<p>康乃德生物制药（NASDAQ:CNTB - 获取免费报告）于周三发布了季度财报。该公司报告每股收益为（$0.31），低于市场共识预期的（$0.24），差距为（$0.07），据 Zacks 报道。</p>
<p>获取 <strong>康乃德生物制药</strong> 的提醒：</p>
<h2>康乃德生物制药股价上涨 4.3%</h2>
<p>周三，CNTB 股价上涨$0.07，达到$1.59。该公司的交易量为 167,832 股，而其平均交易量为 110,888 股。该公司的流动比率为 7.24，速动比率为 7.24，债务与股本比率为 0.01。该公司的市值为 8832 万美元，市盈率为-3.77，贝塔值为-0.14。康乃德生物制药的 50 日移动平均价格为$1.66，200 日移动平均价格为$1.45。康乃德生物制药的 1 年最低价为$0.51，1 年最高价为$2.86。</p>
<h2>华尔街分析师预测增长</h2>
<p>CNTB 已成为多份研究分析报告的主题。Wall Street Zen 在 8 月 22 日的研究报告中将康乃德生物制药的股票评级上调至 “持有”。HC Wainwright 在 8 月 13 日的研究报告中重申了 “买入” 评级，并对康乃德生物制药的股票设定了$7.00 的目标价。Weiss Ratings 在 10 月 8 日的研究报告中重申了对康乃德生物制药的 “卖出（d-）” 评级。BTIG Research 在 10 月 31 日的研究报告中开始覆盖康乃德生物制药，并为该公司设定了 “买入” 评级。最后，Northland Capmk 在 7 月 22 日的研究报告中将康乃德生物制药的股票评级上调至 “强力买入”。一位股票研究分析师给予该股票 “强力买入” 评级，两位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为$7.00。</p>
<p><strong>阅读我们关于 CNTB 的最新研究报告</strong></p>
<h2>对康乃德生物制药的对冲基金看法</h2>
<p>一家机构投资者最近在康乃德生物制药股票中购买了新头寸。XTX Topco Ltd 在第二季度购买了康乃德生物制药控股有限公司赞助的 ADR（NASDAQ:CNTB - 免费报告）的新头寸，根据其最近向证券交易委员会（SEC）提交的 13F 文件。该机构投资者购买了 28,862 股该公司的股票，价值约为 29,000 美元。截至其最近的 SEC 文件，XTX Topco Ltd 持有康乃德生物制药约 0.05% 的股份。目前 58.72% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>康乃德生物制药公司简介</h2>
<p>（获取免费报告）</p>
<p>康乃德生物制药控股有限公司是一家临床阶段的生物制药公司，专注于开发治疗 T 细胞驱动的炎症性疾病的疗法。该公司正在建立一个小分子和抗体的管道，利用功能性 T 细胞检测筛选和发现针对已验证免疫靶点的有效产品候选。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票比康乃德生物制药更好</li>
<li>最大的股票亏损者 - 今天最大的百分比下跌者</li>
<li>为什么多头希望 Palantir 股票大幅下跌</li>
<li>银行股票 - 最值得投资的银行股票</li>
<li>皮萨约翰 27 亿美元的收购提议：未开发价值的价格</li>
<li>电动车股票及其盈利方式</li>
<li>高通是上涨 40% 还是下跌 20%？两种对立观点</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在康乃德生物制药吗？</h2>
<p>在你考虑康乃德生物制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而康乃德生物制药并不在名单上。</p>
<p>虽然康乃德生物制药目前在分析师中有适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

康乃德生物制药

<p>康乃德生物制药 (NASDAQ:CNTB) 报告的季度每股收益 (EPS) 为 ($0.31)，低于分析师预期 $0.07。尽管盈利未达预期，股价仍上涨 4.3%，至 $1.59。该公司的市值为 8832 万美元，市盈率为 -3.77。分析师对该股票的评级不一，普遍目标价为 $7.00。包括 XTX Topco Ltd 在内的机构投资者持有该股票 58.72%</p>

<p>Connect Biopharma (NASDAQ:CNTB - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.07), Zacks reports.</p>
<div class="lb-trans"><p>康乃德生物制药（NASDAQ:CNTB - 获取免费报告）于周三发布了季度财报。该公司报告每股收益为（$0.31），低于市场共识预期的（$0.24），差距为（$0.07），据 Zacks 报道。</p>
</div><p>Get <strong>Connect Biopharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>康乃德生物制药</strong> 的提醒：</p>
</div><h2>Connect Biopharma Trading Up 4.3%</h2>
<div class="lb-trans"><h2>康乃德生物制药股价上涨 4.3%</h2>
</div><p>CNTB traded up $0.07 on Wednesday, hitting $1.59. The company had a trading volume of 167,832 shares, compared to its average volume of 110,888. The company has a current ratio of 7.24, a quick ratio of 7.24 and a debt-to-equity ratio of 0.01. The firm has a market cap of $88.32 million, a P/E ratio of -3.77 and a beta of -0.14. The company's fifty day moving average price is $1.66 and its 200 day moving average price is $1.45. Connect Biopharma has a 1 year low of $0.51 and a 1 year high of $2.86.</p>
<div class="lb-trans"><p>周三，CNTB 股价上涨$0.07，达到$1.59。该公司的交易量为 167,832 股，而其平均交易量为 110,888 股。该公司的流动比率为 7.24，速动比率为 7.24，债务与股本比率为 0.01。该公司的市值为 8832 万美元，市盈率为-3.77，贝塔值为-0.14。康乃德生物制药的 50 日移动平均价格为$1.66，200 日移动平均价格为$1.45。康乃德生物制药的 1 年最低价为$0.51，1 年最高价为$2.86。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>CNTB has been the subject of several research analyst reports. Wall Street Zen raised shares of Connect Biopharma to a &#34;hold&#34; rating in a research note on Friday, August 22nd. HC Wainwright reissued a &#34;buy&#34; rating and issued a $7.00 price objective on shares of Connect Biopharma in a research report on Wednesday, August 13th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Connect Biopharma in a research note on Wednesday, October 8th. BTIG Research initiated coverage on Connect Biopharma in a research report on Friday, October 31st. They set a &#34;buy&#34; rating for the company. Finally, Northland Capmk raised shares of Connect Biopharma to a &#34;strong-buy&#34; rating in a research report on Tuesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $7.00.</p>
<div class="lb-trans"><p>CNTB 已成为多份研究分析报告的主题。Wall Street Zen 在 8 月 22 日的研究报告中将康乃德生物制药的股票评级上调至 “持有”。HC Wainwright 在 8 月 13 日的研究报告中重申了 “买入” 评级，并对康乃德生物制药的股票设定了$7.00 的目标价。Weiss Ratings 在 10 月 8 日的研究报告中重申了对康乃德生物制药的 “卖出（d-）” 评级。BTIG Research 在 10 月 31 日的研究报告中开始覆盖康乃德生物制药，并为该公司设定了 “买入” 评级。最后，Northland Capmk 在 7 月 22 日的研究报告中将康乃德生物制药的股票评级上调至 “强力买入”。一位股票研究分析师给予该股票 “强力买入” 评级，两位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为$7.00。</p>
</div><p><strong>Read Our Latest Research Report on CNTB</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 CNTB 的最新研究报告</strong></p>
</div><h2>Hedge Funds Weigh In On Connect Biopharma</h2>
<div class="lb-trans"><h2>对康乃德生物制药的对冲基金看法</h2>
</div><p>An institutional investor recently bought a new position in Connect Biopharma stock. XTX Topco Ltd purchased a new position in shares of Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 28,862 shares of the company's stock, valued at approximately $29,000. XTX Topco Ltd owned approximately 0.05% of Connect Biopharma as of its most recent SEC filing. 58.72% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一家机构投资者最近在康乃德生物制药股票中购买了新头寸。XTX Topco Ltd 在第二季度购买了康乃德生物制药控股有限公司赞助的 ADR（NASDAQ:CNTB - 免费报告）的新头寸，根据其最近向证券交易委员会（SEC）提交的 13F 文件。该机构投资者购买了 28,862 股该公司的股票，价值约为 29,000 美元。截至其最近的 SEC 文件，XTX Topco Ltd 持有康乃德生物制药约 0.05% 的股份。目前 58.72% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Connect Biopharma Company Profile</h2>
<div class="lb-trans"><h2>康乃德生物制药公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.</p>
<div class="lb-trans"><p>康乃德生物制药控股有限公司是一家临床阶段的生物制药公司，专注于开发治疗 T 细胞驱动的炎症性疾病的疗法。该公司正在建立一个小分子和抗体的管道，利用功能性 T 细胞检测筛选和发现针对已验证免疫靶点的有效产品候选。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Connect Biopharma</li>
<li>Biggest Stock Losers - Today’s Biggest Percentage Decliners</li>
<li>Why Bulls Should Want a Bigger Drop in Palantir Stock</li>
<li>Bank Stocks - Best Bank Stocks to Invest In</li>
<li>Papa John's $2.7 Billion Takeover Bid: A Price on Untapped Value</li>
<li>EV Stocks and How to Profit from Them</li>
<li>Is Qualcomm Up 40% or Down 20%? 2 Contrarian Takes</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比康乃德生物制药更好</li>
<li>最大的股票亏损者 - 今天最大的百分比下跌者</li>
<li>为什么多头希望 Palantir 股票大幅下跌</li>
<li>银行股票 - 最值得投资的银行股票</li>
<li>皮萨约翰 27 亿美元的收购提议：未开发价值的价格</li>
<li>电动车股票及其盈利方式</li>
<li>高通是上涨 40% 还是下跌 20%？两种对立观点</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Connect Biopharma Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在康乃德生物制药吗？</h2>
</div><p>Before you consider Connect Biopharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑康乃德生物制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Connect Biopharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而康乃德生物制药并不在名单上。</p>
</div><p>While Connect Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然康乃德生物制药目前在分析师中有适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

康乃德生物制药（NASDAQ:CNTB）公布财报，每股收益比预期低 0.07 美元